Prosonix is delighted to announce the launch of its new co-crystal development and processing service, aimed specifically at the manufacturing of pharmaceutical co-crystals suitable for use in inhaled and oral medicine, using its proprietary technologies to facilitate co-crystal production at any scale alongside controlled particle size distribution and high purity.

 

Prosonix technologies, such as UMAX^®, DISCUS^®, and USOBR^TM, have been successfully applied to the production of a significant number of co-crystals. The co-crystals produced are very typically of higher purity and with a defined particle size distribution compared with those obtained from standard crystallization techniques. In addition, solubility and dissolution properties of the APIs are significantly improved by co-crystallization. The techniques can be as equally applied for identifying new co-crystals.  Prosonix is using several years of learning to tackle this key emergent area of pharmaceutical development by designing protocols for controlled crystallization and manufacture of pharmaceutical co-crystals in a robust and efficient manner.

Please refer to Pharmaceutical Co-crystals